Meribank Biotech Co

Meribank Biotech Co EBITDA per Share

The EBITDA per Share of Meribank Biotech Co (4724.TWO) as of Oct 16, 2026 is -0.54 TWD. In the previous year, EBITDA per Share was -0.91 TWD — a change of -40.95% (higher).

EBITDA per Share

-0.54TWD

YoY

-40.95%

Last updated:

EBITDA per Share of Meribank Biotech Co is 2025 -0.54 TWD. EBITDA per Share of Meribank Biotech Co was 2024 -0.91 TWD. It decreases by -40.95% higher compared to the previous year.

The Meribank Biotech Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-0.65 TWD
Jan 1, 2020
-0.80 TWD
Jan 1, 2021
-1.11 TWD
Jan 1, 2022
-1.75 TWD
Jan 1, 2023
-1.96 TWD
Jan 1, 2024
-0.91 TWD
Jan 1, 2025
-0.54 TWD
The Meribank Biotech Co EBITDA per Share history
YEAREBITDA per ShareYoY
-0.54TWD-40.95%
-0.91TWD-53.47%
-1.96TWD+11.94%
-1.75TWD+58.26%
-1.11TWD+38.67%
-0.80TWD+22.11%
-0.65TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Meribank Biotech Co Stock analysis

What does Meribank Biotech Co do? Meribank Biotech Co Ltd, listed on the Taiwan Stock Exchange with ticker 4724.TWO and ISIN TW0004724000, is headquartered in Taipei City, Taiwan. The company went public on June 16, 2023. Meribank Biotech focuses on the research and development of stem cell technologies, specifically providing cord blood (hematopoietic stem cells) storage and application services. It also offers storage and application services for placenta and umbilical cord (mesenchymal stem cells), as well as peripheral blood stem cell storage and application services. The company is involved in promoting stem cell transplantation applications and developing new stem cell processing technologies. Additionally, Meribank Biotech engages in the development of allogeneic umbilical cord mesenchymal stem cell manufacturing and therapeutic applications. The firm’s website is https://www.meribank.com.tw/. No further details on its sector, industry, or specific financial figures are provided in the available information. The company operates within the biotechnology sector, concentrating on stem cell-related services and technologies. Its IPO date marks its entry into the public market, with operations centered on the storage and application of various stem cell types for medical and therapeutic purposes. Meribank Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meribank Biotech Co stock

EBITDA per Share of Meribank Biotech Co is -0.54 TWD in 2025.

EBITDA per Share of Meribank Biotech Co changed from -0.91 TWD to -0.54 TWD, representing a -40.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Meribank Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Meribank Biotech Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Meribank Biotech Co